Clinical trials · Nashville, TN
Pancreatic cancer clinical trials in Nashville
We’re tracking 49 recruiting pancreatic cancer studies with a site in or near Nashville — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Nashville
- NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Nashville, TennesseeAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Nashville, TennesseeAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Nashville, TennesseeAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
Study of new RAS inhibitors for GI solid tumors
This trial tests new drugs that target specific RAS mutations in advanced gastrointestinal cancers, like pancreatic or colorectal cancer. It aims to see if these drugs can shrink tumors or slow their growth.
Nashville, TennesseeAges 18 years+ - NCT00899626Recruiting
Collecting stool and tissue markers from people with bowel conditions
This study collects samples (like tissue and other body fluids) from people who are getting a colonoscopy or similar camera test. It aims to find “biomarkers,” which are measurable signals that may help doctors better understand or detect bowel problems such as colorectal cancer, polyps, or inflammatory bowel disease.
Nashville, TennesseeAges 18 years+ - NCT03257033RecruitingPhase 3
Gemcitabine through an artery versus by vein after radiation
This study tests whether giving gemcitabine directly into the artery feeding the pancreas (instead of through an IV) works better after you finish radiation therapy. It may help patients by improving how the medicine reaches the tumor while comparing side effects and outcomes between the two delivery methods.
Nashville, TennesseeAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Nashville, TennesseeAges 18 years+ - NCT04588025Recruiting
MRI study using a special model to measure pancreatic cancer response
This study tests a new, harmless “disposable” setup for MRI scans to measure how pancreatic cancer treatments affect the body. It may help doctors get more accurate MRI measurements, so treatment response can be assessed better.
Nashville, TennesseeAges 19 years+ - NCT04239573Recruiting
Compare pancreatic cyst checkup programs and test markers
This study compares different ways to monitor pancreatic cysts and also measures blood or other test markers to see which approach is more helpful. It may help patients by finding the safest, most effective way to track certain cysts that could otherwise be hard to manage.
Nashville, TennesseeAges 50–75 - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Nashville, TennesseeAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Nashville, TennesseeAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Nashville, TennesseeAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Nashville, TennesseeAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Nashville, TennesseeAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Nashville, TennesseeAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Nashville, TennesseeAges 12 years+ - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Nashville, TennesseeAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Nashville, TennesseeAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Nashville, TennesseeAges 40 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Nashville, TennesseeAges 18 years+ - NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Nashville, TennesseeAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Nashville, TennesseeAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Nashville, TennesseeAges 18 years+
Hear when a new Pancreatic cancer trial opens near Nashville, TN
We’ll email you when one opens near Nashville, TN — at most once a week, no account needed, unsubscribe anytime.
Pancreatic cancer trials in other cities
Where these studies are running near Nashville
Institutions with a site for the recruiting pancreatic cancer studies listed above.
- Vanderbilt University Medical Center · 12 studies
- Sarah Cannon Research Institute · 7 studies
- SCRI Oncology Partners · 7 studies
- Local Institution - 0063
- Research Site
- Tennessee Oncology
- US Oncology Research Network
- Veterans Affairs Medical Center - Nashville
What taking part in a pancreatic cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting pancreatic cancer studies in Tennessee.
Common questions
- Are there pancreatic cancer clinical trials near Nashville?
- Yes. We're currently tracking 49 recruiting pancreatic cancer studies with a site near Nashville, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pancreatic cancer study near Nashville?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Nashville to take part?
- Not necessarily. These studies have a site near Nashville, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pancreatic cancer studies open near Nashville regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.